The neurotology biopharma Otonomy (Nasdaq:OTIC) is planning to liquidate and dissolve its business. It plans to distributing any remaining cash to shareholders after its operations have been suspended and its pipeline assets have been sold.
The company also announced that it had terminated all of its employees effective December 15.
In 2017, Otonomy announced that a Phase 3 clinical study of its pipeline drug Otividex missed its primary endpoint in treating Ménière’s disease. Otividex was an extended-release form of dexamethasone.
In August 2022, it announced disappointing data from a Phase 2 study focused on testing OTO-313 in tinnitus.
At that point, the company laid off 55% of its staff and shifted its focus to OTO-413, a brain-derived neurotrophic factor agonist OTO-413 that yielded a clinically meaningful improvement in a Phase 2a hearing loss study.
Otonomy said it expected to pay roughly $5 million in severance and other…